Skip to main content

Effect of l-theanine tablets in reducing stress-related emotional signs in cats: an open-label field study



L-theanine is an aminoacid found in tea leaves which has relaxing effects in humans and animals. It is a structural analogue of glutamate which can bind glutamate receptors. Although the relaxing action of L-theanine has been shown in humans, laboratory animals and dogs, it has never been published in cats. The goal of this open-label, multicentre and prospective trial was to determine whether an L-theanine based oral supplement (Anxitane®, Virbac, France) could attenuate manifestations of stress in cats under field conditions.

Case presentation

Thirty-three privately owned cats presenting signs associated with stress or fear (inappropriate urination/defecation, fear-induced aggressiveness, hypervigilance/tenseness or physical/functional manifestations of stress) for at least 1 month, were included in the study. They were given L-theanine (Anxitane®, 25 mg twice a day) for 30 days and 20 stress-related parameters were scored at Days 0, 15 and 30. The evolution of some parameters was also rated relative to Day 0. All median scores of the 20 parameters were significantly reduced at D30, and 30/33 cats (91%) had a reduced global score at the end of the study, including 21/33 with ≥50% score reduction. The median (IQR) global scores went from 18 (13–23) at D0 to 11 (8–13) at D15 and 5 (3–12) at D30 (p < 0.0001; Friedman test; significant reduction starting from D15). All the stress-related signs were significantly improved compared to D0, according to the owners, especially inappropriate elimination. Tablet palatability was judged good or very good in 94% of cases with spontaneous intake by cats when given by hand or in food. Tolerance was satisfactory as well, and no side effects were reported, so that most owners (27/33; 82%) were satisfied with the product.


Despite the lack of a placebo group, it can be concluded that L-theanine (Anxitane®) helped to improve the undesirable manifestations of stress in cats in as soon as 15 days, though better results could be seen after 30 days of administration. These encouraging results show that L-theanine can help manage stress-related behaviour, but additional trials with a placebo group should be run to confirm this effect.


Green tea has been used worldwide for centuries and is very much appreciated for its taste and relaxing properties [1, 2]. After the discovery that theanine, an amino acid, was the main component of green tea leaves (Camellia sinensis) responsible for the relaxing effect, many studies have investigated the properties of this molecule (see [2,3,4] for reviews). L-theanine is the main bioavailable form present in tea (1–2% of total leaf weight), and represents around 50% of total free amino acids in tea [2]. In mammals, L-theanine can cross the blood brain barrier, in a dose-dependent manner, in the first hour after administration and remains in the plasma and brain for a few hours [2, 5, 6]. It can now be synthesised or extracted from tea and can be used as an oral dietary supplement for humans or animals.

In humans, L-theanine has been shown to facilitate the generation of alpha waves in the brain that are indicative of a relaxed, awake and alert state, without promoting drowsiness [2, 7,8,9]. L-theanine would also help regulate the physiological parameters usually increased during stressful events (e.g. blood pressure, heart rate, cortisol secretion), which further contributes to the stress-reducing effects [9,10,11,12]. L-theanine’s relaxing effect has also been shown in dogs with fear of humans [13] or storms [14]. After 1 or 2 months of L-theanine administration (twice a day), fearful reactions were reduced. Finally, L-theanine would enable the increase of learning capacities [15, 16].

The relaxing properties of L-theanine (or γ-ethylamino-L-glutamic acid) can mainly be explained by its similarity in structure to glutamate, the most important excitatory neurotransmitter in the brain, which allows the compound to interact with glutamate receptors such as AMPA, kainate, and NMDA (at the glycine site). This antagonistic activity may play a role in neuroprotection against glutamate toxicity [4, 9, 17], and in secretion of dopamine and serotonin in specific brain areas [18].One study also reported the increase of GABA concentration in mice brain following L-theanine administration: this effect probably explains the counteracting activity of L-theanine against caffeine [17]. These effects likely explain the ability of L-theanine to modulate neuronal response involved in mood, stress, pleasure and reward [4, 17,18,19,20,21].

Although the relaxing activity of L-theanine has been shown in humans, laboratory animals and dogs, it has not been published in cats. Cats can show undesirable behaviours when experiencing stressful events, such as urinary marking of furnitures and household structures, excessive scratching, aggressiveness and overgrooming. In addition to these behavioural changes, stress can also lead to recurring physical conditions such as emotional (often qualified as idiopathic) cystitis, chronic digestive signs (vomiting, diarrhoea) and disturbed eating behaviours [22,23,24]. From the pet owner’s stand point, the most unwanted behaviours are urinary marking [25, 26] and excessive scratching [27], which are usually the first signs of discomfort. Before the situation worsens and requires medication, it would be useful to determine if an oral supplement containing L-theanine can reduce stress-related behaviours as in the other species studied so far.

The aim of the present study was to evaluate whether a veterinary L-theanine-based oral supplement (Anxitane® tablets, Virbac) could attenuate signs of stress in cats under field conditions.

Materials and methods

Aim, design and settings

This study was an open-label, multicentre and prospective trial designed to evaluate the impact of L-theanine (Anxitane®) on stress or fear-related reactions, in client-owned cats, in the field. The cats were included in the study regardless of age, breed, sex, origin (conditions of adoption) or lifestyle (indoor or outdoor cats). Of the 11 investigators, 9 were located in France (from 5 regions) and 2 were in Belgium (from 2 different areas). Amoung the 11 investigators 5 of them hold the French Inter School Diploma of Behaviorist Veterinarian and exerted in referral practice.

Case presentation

Inclusion criteria were: occurrence, for at least 1 month, of one or more of the following manifestations of stress: inappropriate urination / defecation, aggressiveness (from fear), hypervigilance / tenseness, inhibition, cohabitation problems, fear of humans or physical manifestations of stress (digestive signs, hypersalivation, excessive body licking or changes in feeding or drinking behaviour).

All cats had to be in good health for inclusion in the study, on the basis of history and a complete physical examination. Clinic pathological testing was not considered mandatory for inclusion so as to avoid stress conditions or animal sedation. Exclusion criteria were: cats with serious chronic illness, or cats receiving supplement products, pheromones or having received any other psychotropic medications for the behaviour condition in the preceding week.

Product and administration

The cats received 25 mg (half a tablet of Anxitane® S, Virbac, France) in the morning and 25 mg in the evening, corresponding to 50 mg of L-theanine per day, for 1 month. Any other oral supplement was forbidden, as well as pheromone applications or drugs. No specific behavioural therapy instructions were given, so as to keep a reproducible environment among the subjects. Nevertheless standard recommendations regarding the feline species were given to each owner (no punishment, elementary rules for feeding, etc).

All cats were treated against external parasites (fipronil spot-on) and internal parasites (milbemycine/praziquantel) at recommended dosages prior to the inclusion.

Interventions and assessments

Each cat was assessed on Days 0, 15 and 30 (D0, D15 and D30), with a physical examination on D0 and D30.

A behavioural examination based on 20 parameters - rated from 0 to 3 - was performed by the veterinarian, according to the owner’s statement. Those parameters included:

  • Neurovegetative signs (9 parameters): polypnea; shivering; mydriasis; piloerection; rolling skin syndrome; vomiting; diarrhoea; hypersalivation; fear-induced urination or defecation;

  • Interspecific interactions (6 parameters): meowing; excessive demands for attention; threats (hissing) or even bites because of irritation (when patted or while playing with the owner); threats (hissing) or even attacks when surprised or because of fear; aggression redirected against people / objects / furniture / tail; avoidance behaviour;

  • Emotional state and its postural expression (5 parameters): inhibition (flattened ears / tendency to crouch/hide); agitation; hypervigilance and hyperaesthesia; tendency to panic / run away or hide; inhibition with licking / stereotypical behaviour.

The scores for the 20 parameters were added to calculate a global score reflecting the presence of undesirable behaviours possibly related to stress in test animals.

The investigators and the owners also had to rate, on a 0% (complete improvement) to 100% (no improvement) scale, their perception of the evolution in the 4 dominant signs as compared to baseline evaluation; these signs were considered stress manifestations: inappropriate elimination; aggressiveness; stress-related signs (hypervigilance, nervousness, fear) and stress-induced functional/organic signs (digestive signs, disturbed eating and drinking behaviours, overgrooming and scratching).

Four other parameters describing elementary behaviours (mandatory for animal survival) were scored, from 0 (normal/regular) to 2 (very disturbed) according to their intensity or frequency: sleep (normal to agitated), appetite (normal/regular to disturbed), drinking (normal/regular to high water consumption) and mood (happy to sad).

Parameters used for behaviour assessment rely on common consensus among French and Belgian behaviourist associations. These recommendations are based upon several publications [28,29,30,31].

The product itself was then evaluated for acceptability, tolerance and owner satisfaction. The first two parameters were scored from 1 (very good) to 4 (poor).

Statistical analysis

The evolution of the parameters over time was compared using the Friedman test followed by adjusted (Holm) pairwise comparisons using the Wilcoxon signed rank test, in case of significance. Only statistical tests giving p < 0.05 were considered significant. Data are presented as median (range) or median (interquartile range = IQR).


In total, 33 cats aged 5 months to 16 years and weighing between 2 and 10.1 kg were included in the study (Table 1). None were excluded after the start of the study. Most cats were European shorthair cats, had been adopted before the age of 1 year and generally came from a relative or a friend, or had been found (Table 1).

Table 1 Demographic data and reason for inclusion of the 33 cats

The main reasons for inclusion were stress-related behavioural signs (hypervigilance, nervousness, fear) in 79% of the cases and inappropriate elimination (45% of the cases) while aggressiveness (24% of the cases) and stress-induced functional/organic signs (mainly changes in feeding or drinking behaviour; 21% of the cases) occurred less often (Table 1). The median (range) age of onset of undesirable behaviours/signs was 1 (0.2–12) year with 67% and 15% of the cats starting to show issues before the age of 1 and from adoption, respectively. In 42% of the cats, such behaviours had been stable since their onset, but had worsened over time in another 58% of the cats.

Scores of stress-related parameters

All the parameters significantly improved (lower score) during the course of the study, except for those which concerned too few animals (< 4 cats: diarrhoea, hypersalivation and redirected aggression). Hypervigilance/hyperesthesia was the parameter with the highest median score at D0 and concerned 27/33 cats (82%). A significant decrease of this median (IQR) score was observed during the course of the study: from 3 (2–3), to 1 (0–2) and 1 (0–1) at D0, D15 and D30 respectively (p < 0.0001). At the end of the study, 8/27 cats (30%) no longer showed the signs. Shivering was the parameter most reduced in frequency since it was detected in 11/33 cats (33%) at the beginning of the trial and in only 3/33 cats (9%) by the end of the study.

The median (IQR) global score significantly decreased from D0: 18 (13–23) to D15: 11 (8–13) and D30: 5 (3–12); p < 0.0001 (Friedman test); Fig. 1. Improvement between D15 and D30 was also statistically significant; (p < 0.05); Fig. 1.The median (IQR) relative reduction of the global score from D0 to D30 was 62% (39–75%). Most of the cats (30/33; 91%) had a reduced score at the end of L-theanine administration and only 3/33 cats (9%) showed no improvement (Fig. 2). The global score was reduced by 50% or more in most cats (21/33; 82%), with 7/33 (21%) showing an excellent response to L-theanine (score reduced by 80% or more; Fig. 2).

Fig. 1
figure 1

Evolution of the global score (sum of the scores for the 20 stress-related parameters evaluated) over time during the study. Data are presented as median/1st and 3d quartiles/minimum and maximum values. ** p < 0.01 compared to D0 according to adjusted pairwise comparison (Friedman test: p < 0.0001)

Fig. 2
figure 2

Distribution of the cats according to their response to L-theanine. The reduction in the global score reflecting stress-related parameters was calculated at D30 relative to D0 (%) for each cat. The number of cats showing no reduction (no response to L-theanine), a 1–29% reduction (poor response), a 30–49% reduction (fair response), a 50–79% reduction (good response) or a reduction of 80% or more (excellent response to L-theanine) in their global score, are reported (total n = 33)

Improvement of signs (owner perception)

According to the owners, among the 4 stress-related signs which were evaluated, the inappropriate elimination (urination/defecation) was the one that improved the most (Table 2). At the end of the study, 10/18 cats (66%) were deemed to have stopped showing this inappropriate behaviour (score of 0% at D30) and 5/13 (38%) to have stopped showing signs of disturbed grooming, disturbed food or water intake, or digestive signs. Hypervigilance/tenseness/fear and aggressiveness were the least improved parameters, with 3/31 (10%) and 3/16 (19%) cats, respectively, deemed to have stopped showing those signs. Still, all the parameters significantly improved according to the median of ratios given by the owners (Table 2).

Table 2 Relative severity of stress-related signs, compared to D0 (%)

Sleep, appetite, drinking and mood evaluation

Of the 12 cats with sleeping issues at D0 (score > 0), 9/12 (75%) were judged normal at the end of the study (significant reduction of scores, Friedman test, p < 0.05). Similarly, of the 16 cats described as sad or unhappy (score > 0 for mood), 12/16 (75%) were normal/happy at the end of L-theanine administration (significant reduction in scores, Friedman test, p < 0.001). Appetite and drinking behaviours also improved in some cats but not significantly. 2/9 (22%) and 1/2 (50%) of the cats with appetite or drinking issues at baseline became normal (score of 0) at the end of the study.

Ease of administration, tolerance and owner’s satisfaction

The ease of administration of the tablets was considered to be very good by 22/33 (67%) owners, good by 9/33 (27%) and fair by 2/33 (6%) (Fig. 3). The median (IQR) score for this parameter was of 1 (1–2) on a 1–4 scale. Tolerance was also deemed very good or good by all the owners (Fig. 3) with the same median (IQR) score. Most owners were very satisfied or satisfied [13/33 (39.5%) and 14/33 (42.5%), respectively] and only 6/33 (18%) owners were poorly or not satisfied (Fig. 3).

Fig. 3
figure 3

Ease of administration and tolerance of Anxitane®. The owners had to judge the ease of administration of the tablets (blue) and their tolerance (green). The number of owners judging these parameters as very good, good, fair or poor are reported here

Adverse events

No serious adverse events were reported during the course of the study. Two cats were more sleepy/apathetic during the first days of administration, leading to a reduction of doses (once a day instead of twice a day) in one of them. Both cats improved (following the dose reduction for the first one and spontaneously within 3 days for the second one) and were kept in the trial.


Almost all of the parameters evaluated were improved during the course of this study in 33 cats with stress-related signs. The behaviour of most of the cats improved after 15 or 30 days of L-theanine administration, leading to high owner satisfaction.

However, this study was open-label and did not contain a control group. Conclusions should therefore be taken with caution as owners/vets could have expected some sort of improvement during this type of trial. Still, the extent of the decrease in undesirable stress-related signs observed during the study in most cats is promising and suggests that L-theanine could calm and relax cats. Especially, some signs like inappropriate urinating, excessive grooming, hypervigilance, excessive demands of attention or panicking were improved as of Day 15. Irritability also decreased and cats were found to be more calm and gentle at the end of the study.

Among stress-related signs, inappropriate urination (whether due to excessive marking or inappropriate elimination) was probably the most bothersome for the owners and is one of the most frequent causes of consultation [24,25,26,27]. This type of sign is mainly due to a lack of adaptation to the environment or to the social conflicts a cat faces on a daily basis. Interestingly, inappropriate urination disappeared in 66% of the cats in this study, despite the lack of a specific behavioural therapy.

In cats (and dogs), many factors can induce stress-related behavioural signs [23,24,25]: an unpleasant experience during development, unsuitable living conditions and environment, bad relationships with owners or other animals, or pain and pathological conditions. Conflicts with the owners can create and help perpetuate unwanted signs, and the reverse can be true as well. Behavioural therapy can help owners understand and face the condition and adapt their behaviour or modify the cat’s environment in order to reduce feline stress. Instead of reprimanding the animal (especially in case of inappropriate urination or nervousness), the owner will be more understanding which in turn will help the cat. Although behavioural therapy is the mainstay of management of behavioural issues, pheromones, nutritional supplements or psychoactive drugs can also be prescribed to decrease anxiety [22]. In the current study, although no specific behavioural modifications were implemented, some basic behavioural therapy advice was given to the owners. It is possible that this advice contributed, at least in part, to the results obtained. We feel, however, that the important reduction in unwanted signs recorded in this study cannot be attributed solely to owners given the absence of specific behavioural advice provided by veterinarians. Further studies could be performed to assess potential additional or synergistic benefits of Anxitane® tablets over behavioural therapy alone.

Over time, it was found in this trial that most signs significantly improved as of Day 15. Since product tolerance was very good, a longer administration over 2–3 months could have helped reduce further unwanted signs still detected at 1 month in some cats, like aggressiveness or hypervigilance/tenseness/fear. Indeed, it is generally advised to carry on administration of a stress reducing product for a few months since effects can be seen only after 8 or 16 weeks of administration [13, 32].

In this study, L-theanine significantly helped improve the sleep and mood of cats but did not have the same impact on disturbed eating and drinking behaviours. Again, a longer administration could have helped reduce the issues but other concurrent ailments (endocrine or renal, for example) cannot be excluded and should be checked in case the behavioural signs persist.

Although no study describing the mechanism of action of L-theanine in cat is available, it is highly likely that it is similar to what was described earlier in laboratory animals (especially, an action on glutamate receptors and release of neuromediators) [4, 17, 19, 21]. More specifically, no sedative effect of L theanine has been previously reported in human, in rats, nor in dogs [2, 7, 8, 13, 14] .Therefore we expect that the effects observed in this study are due to a decrease of the stress level (and not to a sedative effect).

Thus, as in dogs [13, 14], L-theanine can be of value as an oral dietary supplement in cats, as it is safe and easy to give to individuals presenting with signs of stress (hypervigilance, mydriasis, rolling skin syndrome, excessive meowing, inappropriate elimination, etc.), in order to help them cope with changes in their environment.


Cats are sensitive to environmental changes (e.g. change in territory or owners and occasional stressful events) and can show discrepancies with the feline ethogram. Reactions can vary among cats and some may develop behavioural signs or even functional/organic signs. They can become hypervigilant, show signs of fear, and in many cases, urinate inappropriately. These behaviours are unwanted for both the cats and their owners, and the latter can increase feline stress by the way they handle the situation. Although this study does not contain any control group, it suggests that in stressed cats, administration of L-theanine (Anxitane®) twice daily may help improve undesirable signs in as soon as 15 days, though better results were seen after 30 days of administration. These encouraging results showed that L-theanine can help manage stress related behaviour, although additional trials with a placebo group should be run to confirm this effect.


  1. Nobre AC, Rao A, Owen GN. L-theanine, a natural constituent in tea, and its effect on mental state. Asia Pac J Clin Nutr. 2008;17(Suppl 1):167–8.

    CAS  PubMed  Google Scholar 

  2. Juneja LR, Chu DC, Okubo T, Nagato Y, Yokogoshi H. L-theanine-a unique amino acid of green tea and its relaxation effect in humans. Trends Food Sci Technol. 1999;10:199–204.

    Article  CAS  Google Scholar 

  3. Einöther SJ, Martens VE. Acute effects of tea consumption on attention and mood. Am J Clin Nutr. 2013;98(6 Suppl):1700S–8S.

    Article  Google Scholar 

  4. Kakuda T. Neuroprotective effects of the green tea components theanine and catechins. Biol Pharm Bull. 2002;25(12):1513–8.

    Article  CAS  Google Scholar 

  5. Terashima T, Takido J, Yokogoshi H. Time-dependent changes of amino acids in the serum, liver, brain and urine of rats administered with theanine. Biosci Biotechnol Biochem. 1999;63(4):615–8.

    Article  CAS  Google Scholar 

  6. Unno T, Suzuki Y, Kakuda T, Hayakawa T, Tsuge H. Metabolism of theanine, gamma-glutamylethylamide, in rats. J AgricFodd Chem. 1999;47:1593–6.

    Article  CAS  Google Scholar 

  7. Kobayashi A, Nagato Y, Aoi N, Juneja LR, Kim M, Yamamoto T, Sugimoto S. Effects of l-theanine on the release of α-brain waves in human volunteers. Nippon Nogeikagaku Kaishi. 1998;72:153–7.

    Article  CAS  Google Scholar 

  8. Song CH, Jung JH, Oh JS, Kim KS. Effects of Theanine on the Release of Brain Alpha Wave in Adult Males. Korean J Nutr. 2003;36(9):918–23 [Korean].

    CAS  Google Scholar 

  9. White DJ, de Klerk S, Woods W, Gondalia S, Noonan C, Scholey AB. Anti-stress, Behavioural and Magnetoencephalography effects of an L-Theanine-based nutrient drink: a randomised, double-blind, placebo-controlled, crossover trial. Nutrients. 2016;8(1):1–19.

    Article  Google Scholar 

  10. Yokogoshi H, Kobayashi M. Hypotensive effect of γ-glutamylethylamide in spontaneously hypertensive rats. Life Sci. 1998;62:1065–8.

    Article  CAS  Google Scholar 

  11. Kimura K, Ozeki M, Juneja LR, Ohira H. L-Theanine reduces psychological and physiological stress responses. Biol Psychol. 2007;74(1):39–45.

    Article  Google Scholar 

  12. Yoto A, Motoki M, Murao S, Yokogoshi H. Effects of L-theanine or caffeine intake on changes in blood pressure under physical and psychological stresses. J Physiol Anthropol. 2012;31:28.

    Article  Google Scholar 

  13. Araujo JA, De Rivera C, Ethier JE, Landsberg GM, et al. Anxitane tablets reduce fear of human beings in a laboratory model of anxiety-related behavior. J Vet Behav. 2010;5:268–75.

    Article  Google Scholar 

  14. Pike AL, et al. An open-label prospective study of the use of l-theanine (Anxitane) in storm-sensitive client-owned dogs. J Vet Behav: Clin Applications Res. 2015;10(4):324–31.

    Article  Google Scholar 

  15. Berteselli GV, Michelazzi M. Use of L-theanine tablets (Anxitane TabletsTM) and behavior modification for treatment of phobias in dogs: a preliminary study. Proceedings of the 6th International Veterinary Behavior Meeting, Riccione, Italy. 2007:114–5.

  16. Yamada T, Terashima T, Honma H, Nagata S, Okubo T, Juneja LR, Yokogoshi H. Effects of theanine, a unique amino acid in tea leaves, on memory in a rat behavioral test. Biosci Biotechnol Biochem. 2008;72(5):1356–9.

    Article  CAS  Google Scholar 

  17. Kimura R, Murata T. Influence of alkylamides of glutamic acid and related compounds on the central nervous system. I central depressant effect of theanine. Chem Pharm Bull. 1971;19:1257–61.

    Article  CAS  Google Scholar 

  18. Yokogoshi H, Mochizuki M, Saitoh K. Theanine-induced reduction of brain serotonin concentration in rats. Biosci Biotechnol Biochem. 1998;62(4):816–7.

    Article  CAS  Google Scholar 

  19. Kakuda T, et al. Inhibition by theanine of binding of [3H]AMPA, [3H]Kainate, and [3H]MDL 105,519 to glutamate receptors. BiosciBiotechnol Biochem. 2002;66:2683–6.

    Article  CAS  Google Scholar 

  20. Li C, Tong H, Yan Q, Tang S, Han X, Xiao W, Tan Z. L-Theanine improves immunity by altering TH2/TH1 cytokine balance, brain neurotransmitters, and expression of phospholipase C in rat hearts. Med Sci Monit. 2016;22:662–9.

    Article  CAS  Google Scholar 

  21. Yokogoshi H, Terashima T. Effect of theanine, γ-glutamylethylamide, on brain monoamines, striatal dopamine release and some kinds of behavior in rats. Nutrition. 2000;16:776–7.

    Article  CAS  Google Scholar 

  22. Amat M, Camps T, Manteca X. Stress in owned cats: behavioural changes and welfare implications. J Feline Med Surg. 2016;18(8):577–86.

    Article  Google Scholar 

  23. Dramard V. Le comportement du chat de A à Z. Paris: Ulmer; 2012. p. 124.

    Google Scholar 

  24. Dehasse J. Tout sur la psychologie du chat. Paris: Odile Jacob; 2005. p. p138–43.

    Google Scholar 

  25. Horwitz DF. Behavioral and environmental factors associated with elimination behavior problems in cats: a retrospective study. Appl Anim Behav Sci. 1997;52(1):129–37.

    Article  Google Scholar 

  26. Pryor PA, Hart BL, Bain MJ, Cliff KD. Causes of urine marking in cats and effects of environmental management on frequency of marking. J Am Vet Med Assoc. 2001;219(12):1709–13.

    Article  CAS  Google Scholar 

  27. Mengoli M, Mariti C, Cozzi A, Cestarollo E, Lafont-Lecuelle C, Pageat P, Gazzano A. Scratching behaviour and its features: a questionnaire-based study in an Italian sample of domestic cats. J Feline Med Surg. 2013;15(10):886–92.

    Article  Google Scholar 

  28. Gagnon AC, Chaurand JP, Larue JF. Le comportement du chat et ses troubles. Maisons-Alfort: Editions du point vétérinaire; 1995. p. 288.

    Google Scholar 

  29. Buffington CA, Chew DJ, Dibartola SP. Interstitial cystitis in cats. Vet Clin North Am Small An Pr. 1996;26(2):317–26.

    Article  CAS  Google Scholar 

  30. Overall K. Clinical behavioral medicine for small animals. Saint Louis: Editions Mosby; 1997.

    Google Scholar 

  31. Dehasse J. L’éducation du chat. Québec: Le jour éditeur; 2000. p. 141.

    Google Scholar 

  32. Mills DS, Redgate SE, Landsberg GM. A meta-analysis of studies of treatments for feline urine spraying. PLoS One. 2011;6(4):e18448.

    Article  CAS  Google Scholar 

Download references


The authors would like to thank the reviewers for their careful reading of this document and the corrections they have brought.


This study was funded by Virbac.

Availability of data and materials

The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

All the data generated or analysed during this study are included in this published article [and its supplementary information files].

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Author information

Authors and Affiliations



VD was the monitor of the study. The protocol was designed by VD and LK. The statistical analysis was performed by CSN in collaboration with Sandrine Fournel from the Virbac R&D department. All the authors read and approved the final version of the article.

Corresponding author

Correspondence to V Chala.

Ethics declarations

Ethics approval and consent to participate

All the owners had to sign an informed consent to participate.

Following the EU Directive from November 24th 1986, related to protection of animals used for experimental purposes, no declaration to an Ethic Review Committee (ERC) was required until 2013.

The French reglementation also followed the same rules (decree-law number 2001–464, May 29th 2001, modifying the decree number 87–848, October 19th 1987).

The study was run between 2006 and 2007, so that no declaration to an ERC was done at the time. Moreover no invasive procedures were performed, and no placebo group was implemented.

Consent for publication

Not applicable.

Competing interests

CN, CSN, VC an CR are employees of Virbac.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dramard, V., Kern, L., Hofmans, J. et al. Effect of l-theanine tablets in reducing stress-related emotional signs in cats: an open-label field study. Ir Vet J 71, 21 (2018).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: